Recent FDA approval of its Laboratorios Liconsa, together with the purchase in the US of Everett Laboratories for €29 million, reaffirms the presence of the Spanish pharmaceutical company in the United States.

The Liconsa manufacturing facility, located in the municipality of Azuqueca de Henares (Guadalajara) and property of the multinational pharmaceutical company Chemo, has received authorization from the US healthcare authority FDA (Food and Drug Administration) to sell pharmaceuticals that it manufactures at its facilities. The first product sold by the company will be Terbinafina Tablets.

Chemo will export the production from its Spanish plant to the major international markets, selling its medicines in more than 60 countries. This will include the United States, which represents by itself half of the worldwide pharmaceutical market. “FDA authorization is an international seal of approval for our products”, states Mr. Leandro Sigman, General Manager of the company.

The acquisition in March of Everett Laboratories, an American firm specializing in gynecology, consolidates Chemo’s future in the US. Sigman affirms that this laboratory “will strengthen the women’s healthcare business, creating sales synergies such as access to the medical-scientific community and the strength of the sales platform, and doesn’t rule out alternative therapy lines”.

Among Chemo’s near-term plans are the launch of a new gynecology affiliate in Germany, and the purchase of 50% of a company in Brazil.